January 2021 | Targeted Therapies in Oncology

Unique Immunotherapy Combinations Come to the Forefront at SITC Meeting

January 27, 2021

Clinical Articles

In this trial, the previous observation of liver toxicity using CD137 agonism was not observed, suggesting a safe neoadjuvant dosing. Indeed, 30% of patients demonstrated pathologic responses. Further research may combine a way of overcoming immune checkpoint pathways with stimulatory agonists.

Phase 3 COSMIC-313 Trial Explores Triplet Therapy in Advanced Renal Cell Carcinoma

January 26, 2021

Clinical Articles

The safety and efficacy of cabozantinib plus nivolumab and ipilimumab versus nivolumab/ipilimumab will be evaluated in 676 treatment-naïve patients with advanced or metastatic renal cell carcinoma (RCC) in the phase 3 COSMIC-313 trial.

Urelumab Combo Leads to Improved Pathologic Response in Resectable PDAC

January 25, 2021

Clinical Articles

Improved antitumor activity of the triplet combination of urelumab, a GVAX vaccine, and nivolumab was observed in patients with resectable pancreatic ductal adenocarcinoma, according to findings from a 3-arm phase 1/2 trial.

MBCC Offers Review of Burgeoning Advancements in Breast Cancer Management

January 24, 2021

Clinical Articles

The virtual 38th Annual Miami Breast Cancer Conference®, hosted by Physicians’ Education Resource®, LLC will feature presentations from industry thought leaders on innovations in the arena of breast cancer treatment, including topics about systemic therapy and beyond.

How Pharmaceutical Innovation Is Saving the World

January 24, 2021

Clinical Articles

This was the fastest vaccine development program in history, and it’s not even close. David Pride, MD, PhD, a microbiologist at the University of California, San Diego, estimates that vaccines typically take 10 to 15 years to develop. Until the COVID-19 pandemic, the fastest development timeline was 4 years, for the mumps vaccine.

Efficacy of Frontline Atezolizumab Combo Is Comparable Regardless of Primary Urothelial Cancer Location

January 23, 2021

Clinical Articles

An exploratory analysis of the phase 3 IMvigor130 trial demonstrated that the benefit of frontline atezolizumab added to gemcitabine and platinum chemotherapy was maintained in patients with urothelial cancer, regardless of the site of the primary tumor.

New Metastatic Cervical Cancer Treatments Give Hope

January 21, 2021

Clinical Articles

Investigators treating patients with gynecologic malignancies are optimistic that multiple clinical trials exploring new second-line cervical cancer treatments will result in a much-anticipated breakthrough for the field.